Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DeLauro wants FDA approvals list

This article was originally published in The Tan Sheet

Executive Summary

Concerned that commercial and political interests "permeated the culture" of FDA and led to the approval of unsafe or ineffective products, Rep. Rosa DeLauro, D-Conn., requests the agency list all drugs, devices and biologics it approved or cleared in the final three months of the Bush administration. The chairwoman of the Appropriations subcommittee with FDA oversight also asks acting FDA Commissioner Frank M. Torti in a Feb. 12 letter about agency decisions about the generally recognized as safe status for food products made between November 2008 and January 2009. FDA has until Feb. 26 to respond to DeLauro's request, which follows a January letter from agency scientists that "corrupt" FDA managers pushed approval of questionable products (1"The Tan Sheet" Jan. 19, 2009, p. 16)

You may also be interested in...



DeLauro Adds FDA Scientists’ Complaint To Her List Of Agency Problems

FDA scientists' recent complaint to the Obama transition team that the agency is "fundamentally broken" adds fuel to Rep. Rosa DeLauro's fire to establish separate food and drug agencies

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail

Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.

Topics

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel